Skip to content
Technology
Pipeline
News
Press
People
Partners
Careers
Contact
Menu
Technology
Pipeline
News
Press
People
Partners
Careers
Contact
EA-2353 has the potential to reverse the loss of vision in patients with Retinitis Pigmentosa
Prev
Previous
Endogena Completes Series A with Total Funding of $29 million to Progress Treatments for Degenerative Diseases of the Eye
Next
Michael Lai joins Endogena as Medical Director
Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
